Date:August 15, 2022
Your Name:Fan Zhang
Manuscript Title: _A patient with advanced lung squamous cell carcinoma who progressed on albumin boun
paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus
pembrolizumab: a case report
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	None
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	None
3	Royalties or licenses	None	None
4	Consulting fees	None	None

-	Dayman to a barrancia fam	None	Maria
5	Payment or honoraria for	None	None
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	1	
6	Payment for expert	None	None
	testimony		
7	Support for attending meetings and/or travel	None	None
	meetings and/or traver		
8	Patents planned, issued or	None	None
	pending		, xee
	P		
9	Participation on a Data	None	None
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	None
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	None
12	Receipt of equipment,	None	None
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	None
	financial interests		

None.

Please place an "X" next to the following statement to indicate your agreement:

Date:August 15, 2022
Your Name:Yu Xu
Manuscript Title: _A patient with advanced lung squamous cell carcinoma who progressed on albumin bour
paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus
pembrolizumab: a case report
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None None	None None
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	None
3	Royalties or licenses	None	None
4	Consulting fees	None	None

-	Dayman to a barrancia fan	None	Maria
5	Payment or honoraria for	None	None
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	1	
6	Payment for expert	None	None
	testimony		
7	Support for attending meetings and/or travel	None	None
	meetings and/or traver		
8	Patents planned, issued or	None	None
	pending		, xee
	P		
9	Participation on a Data	None	None
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	None
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	None
12	Receipt of equipment,	None	None
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	None
	financial interests		

None.

Please place an "X" next to the following statement to indicate your agreement:

Date:August 15, 2022
Your Name:Shenghu Guo
Manuscript Title: _A patient with advanced lung squamous cell carcinoma who progressed on albumin bound
paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus
pembrolizumab: a case report
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	None
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	None
3	Royalties or licenses	None	None
4	Consulting fees	None	None

5	Payment or honoraria for lectures, presentations,	None	None
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	None
7	Support for attending meetings and/or travel	None	None
8	Patents planned, issued or	None	None
	pending		
9	Participation on a Data	None	None
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	None
10	in other board, society,	None	None
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	None
12	Receipt of equipment,	None	None
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	None
	financial interests		

None

Please place an "X" next to the following statement to indicate your agreement:

Date: August 15, 2022
Your Name:Suping Li
Manuscript Title: A patient with advanced lung squamous cell carcinoma who progressed on albumin bound
paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus
pembrolizumab: a case report
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	None
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	None
3	Royalties or licenses	None	None
4	Consulting fees	None	None

5	Payment or honoraria for lectures, presentations,	None	None
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	None
7	Support for attending meetings and/or travel	None	None
8	Patents planned, issued or	None	None
	pending		
9	Participation on a Data	None	None
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	None
10	in other board, society,	None	None
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	None
12	Receipt of equipment,	None	None
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	None
	financial interests		

None

Please place an "X" next to the following statement to indicate your agreement:

Date:August 15, 2022
Your Name:Ke Ma
Manuscript Title:A patient with advanced lung squamous cell carcinoma who progressed on albumin boun
paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus
pembrolizumab: a case report
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present	None	None
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	None
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	None
4	Consulting fees	None	None

-	Dayman to a barrancia fan	None	Maria
5	Payment or honoraria for	None	None
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	1	
6	Payment for expert	None	None
	testimony		
7	Support for attending meetings and/or travel	None	None
	meetings and/or traver		
8	Patents planned, issued or	None	None
	pending		, xee
	P		
9	Participation on a Data	None	None
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	None
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	None
12	Receipt of equipment,	None	None
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	None
	financial interests		

None.

Please place an "X" next to the following statement to indicate your agreement:

Date:August 15, 2022
Your Name:Junyan Wang
Manuscript Title: _A patient with advanced lung squamous cell carcinoma who progressed on albumin bound
paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus
pembrolizumab: a case report
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	None
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	None
3	Royalties or licenses	None	None
4	Consulting fees	None	None

-	Dayman to a barrancia fan	None	Maria
5	Payment or honoraria for	None	None
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	1	
6	Payment for expert	None	None
	testimony		
7	Support for attending meetings and/or travel	None	None
	meetings and/or traver		
8	Patents planned, issued or	None	None
	pending		, xee
	P		
9	Participation on a Data	None	None
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	None
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	None
12	Receipt of equipment,	None	None
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	None
	financial interests		

None.

Please place an "X" next to the following statement to indicate your agreement:

Date:August 15, 2022	
Your Name:Suju Wei	
Manuscript Title: A patient with advanced lung squamous cell carcinoma who progressed on albumin bo	ound
paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus	
pembrolizumab: a case report_	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
Time frame: Since the initial planning of the work					
1	All support for the present	None	None		
	manuscript (e.g., funding,				
	provision of study materials,				
	medical writing, article				
	processing charges, etc.)				
	No time limit for this item.				
		Time frame: past	36 months		
2	Grants or contracts from	None	None		
	any entity (if not indicated				
	in item #1 above).				
3	Royalties or licenses	None	None		
4	Consulting fees	None	None		

	T	T	
5	Payment or honoraria for	None	None
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	None
	testimony		
	,		
7	Support for attending	None	None
'	meetings and/or travel	None	None
	lineetings and/or traver		
8	Patents planned, issued or	None	None
	pending		
9	Participation on a Data	None	None
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	None
10	in other board, society,	- None	Tions and the second se
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	None
11	Stock of Stock options	140110	None
12	Descipt of agricument	None	None
12	Receipt of equipment,	None	None
	materials, drugs, medical		
	writing, gifts or other		
42	services	A1	
13	Other financial or non-	None	None
	financial interests		

None

Please place an "X" next to the following statement to indicate your agreement: